Estrogen and neuroprotection: From clinical observations to molecular mechanisms

Dialogues in Clinical Neuroscience

Volumn 4, Issue 2, 2002, Pages 149-162

  Dubal, Dena B ^a   Wise, Phyllis M ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Cerebral ischemia; Cognition, brain injury; Estradiol; Estrogen; Estrogen replacement therapy; Menopause; Neuroprotection; Stroke

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ORAL CONTRACEPTIVE AGENT; PROGESTERONE;

AGING; ALZHEIMER DISEASE; BRAIN INJURY; BRAIN ISCHEMIA; CELL SURVIVAL; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG EFFECT; DRUG RECEPTOR BINDING; ESTROGEN ACTIVITY; ESTROGEN THERAPY; HIGH RISK POPULATION; HORMONE RECEPTOR INTERACTION; HUMAN; LIFESPAN; MEMORY; MENOPAUSE; MOLECULAR MECHANICS; NERVE CELL LESION; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; POSTMENOPAUSE; QUALITY OF LIFE; REVIEW; STROKE; TREATMENT OUTCOME; VEIN THROMBOSIS;

EID: 0037992822     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (148)

1. vom Saal FS, Finch CE, Nelson JF. Natural history and mechanisms of reproductive aging in humans, laboratory rodents, and other selected vertebrates. In: Knobil E, Neill JD, eds. The Physiology of Reproduction. New York, NY: Raven Press; 1994:1213-1314.
2. Wise PM. New understanding of the complexity of the menopause and challenges for the future. In: Bellino FL, ed. Proceedings of the International Symposium on the Biology of the Menopause. Norwell, Mass: Springer; 2000: 1-8.
3. Speroff L. Postmenopausal hormone therapy and breast cancer. Obstet Gynecol. 1996;87:44S-53S.
4. Hammond CB. Menopause and hormone replacement therapy: an overview. Obstet Gynecol. 1996;87:2S-15S.
5. Lindsay R. The menopause and osteoporosis. Obstet Gynecol. 1996;87:16S-19S.
6. Sherwin BB. Hormones, mood, and cognitive functioning in postmenopausal women. Obstet Gynecol. 1996;87:20S-26S.
7. Wild RA. Estrogen: effects on the cardiovascular tree. Obstet Gynecol. 1996;87:27S-35S.
8. Sullivan JM, Fowlkes LP. The clinical aspects of estrogen and the cardiovascular system. Obstet Gynecol. 1996;87:36S-43S.
9. Prior JC, Vigna YM, Wark JD, et al. Premenopausal ovariectomy-related bone loss: a randomized, double-blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate. J Bone Miner Res. 1997;12:1851-1863.
10. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology. 1997;48:1517-1521.
11. Henderson VW, Watt L, Buckwalter JG. Cognitive skills associated with estrogen replacement in women with Alzheimer's disease. Psychoneuroendocrinology 1996;21:421-430.
12. Wise PM, Dubal DB, Wilson ME, Rau SW, Liu Y. Estrogens: trophic and protective factors in the adult brain. Front Neuroendocrinol. 2001;22:33-66.
13. Wise PM, Dubal DB, Wilson ME, Rau SW, Böttner M. Minireview: Neuroprotective effects of estrogen - new insights into mechanisms of action. Endocrinology. 2001;142:969-973.
14. Shlipak MG, Angeja BG, Go AS, Frederick PD, Canto JG, Grady D. Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women. Circulation. 2001;104:2300-2304.
15. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Circulation. 2001;104:2300-2304.
16. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
17. Sherwin BB. Estrogen effects on cognition in menopausal women. Neurology. 1997;48:S21-S26.
18. Sherwin BB, Carlson LE. Estrogen and memory in women. J Soc Obstet Gynecol Can. 1997;19:7-13.
19. Kampen DL, Sherwin BB. Estrogen use and verbal memory in healthy postmenopausal women. Obstet Gynecol. 1998;83:979-983.
20. Sherwin BB. Estrogenic effects on memory in women. Ann N Y Acad Sci. 1994;743:213-231.
21. Schmidt R, Fazekas F, Reinhart B, et al. Estrogen replacement therapy in older women: a neuropsychological and brain MRI study. J Am Geriatr Soc. 1996;44:1307-1313.
22. Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology. 1988;13:345-357.
23. Birge SJ. The role of estrogen in treatment of Alzheimer's disease. Neurology. 1997;48:S36-S41.
24. Henderson VW, Paganini-Hill A. Estrogen and Alzheimer's disease. J Soc Obstet Gynecol Can. 1997;19:21-28.
25. Fillit H. Estrogens in the pathogenesis and treatment of Alzheimer's disease in postmenopausal women. Ann N Y Acad Sci. 1994;743:233-239.
26. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med. 1996;156:2213-2217.
27. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol. 1994;140:256-261.
28. Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet. 1996;348:429-432.
29. Asthana S, Craft S, Baker LD, et al. Cognitive and neuroendocresponse to transdermal esrogen in postmenopausal wome Alzheimer's disease: results of a placebo-controlled, double-blinstudy. Psychoneuroendocrinology. 1999;24:657-677.
30. Waring SC, Rocca WA, Petersen RC, O'Brien PC, Tangalos EG, KoPostmenopausal estrogen replacement therapy and risk of AD. A tion-based study. Neurology. 1999;52:965-970.
31. Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzdisease in women. Randomized, double-blind, placebo-controlle Neurology. 2000;54:295-301.
32. Marder K, Sano M. Estrogen to treat Alzheimer's disease: too litlate? So what's a woman to do? Neurology. 2000;54:2035-2037.
33. Wang PN, Liao SQ, Liu RS, et al. Effects of estrogen on cognition, mocerebral blood flow in AD. A controlled study. Neurology. 2000;54:2061
34. Robinson D, Friedman L, Marcus R, Tinklenberg J, Yesavage J. Ereplacement therapy and memory in older women. J Am Geri 1994;42:919-922.
35. Henderson VW, Paganini-Hill A, Emanuel CK, Dunn ME, Buckw Estrogen replacement therapy in older women. Arch Neurol. 1994;51:8
36. Shaywitz SE, Shaywitz BA, Pugh KR, et al. Effect of estrogen o activation patterns in postmenopausal women during working tasks. JAMA. 1999;281:1197-1202.
37. Resnick SM, Maki PM, Golski S, Kraut MA, Zonderman AB. Effects of estrogen replacement therapy on PET cerebral blood flow and neuropsychological performance. Horm Behav. 1998;34:171-182.
38. Resnick SM, Metter EJ, Zonderman AB. Estrogen replacement therapy and longitudinal decline in visual memory. A possible protective effect? Neurology. 1997;49:1491-1497.
39. Honjo H, Tanaka K, Kashiwagi T, et al. Senile dementia-Alzheimer's type and estrogen. Horm Metab Res. 1995;27:204-207.
40. Fillit H, Weinreb H, Cholst I, et al. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology. 1986;11:337-345.
41. Barrett-Connor E, Kritz-Silverstein D. Estrogen replacement therapy and cognitive function in older women. JAMA. 1993;269:2637-2641.
42. Brenner DE, Kukull WA, Stergachis A, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a populationbased case-control study. Am J Epidemiol. 1994;140:262-267.
43. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease: a randomized controlled study. Alzheimer's Disease Cooperative Study. JAMA. 2000;283: 1007-1015.
44. Paganini-Hill A. Hormone replacement therapy and stroke: risk, protection or no effect? Maturitas. 2001;38:243-261.
45. Paganini-Hill A. Estrogen replacement therapy and stroke. Prog Cardiovasc Dis. 1995;38:223-242.
46. Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med. 1993;329:247-256.
47. Kannel WB, Thom TJ. The incidence, prevalence and mortality of cardiovascular disease. In: Schlant RC, Alexander RW, ed. The Heart. 8th ed. New York, NY: McGraw-Hill; 1994:185-197.
48. American Heart Association. 2001 Heart and Stroke Statistical Update. Dallas, Texas: American Heart Association; 2001.
49. Cefalu WT. The use of hormone replacement therapy in postmenopausal women with type 2 diabetes mellitus. J Womens Health Gend Based Med. 2001;10:241-255.
50. Palin SL, Kumar S, Sturdee DW, Barnett AH. HRT in women with diabetes-review of the effects on glucose and lipid metabolism. Diabetes Res Clin Pract 2001;54:67-77.
51. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives. JAMA. 2000;284:72-78.
52. Gutthann SP, Garcia Rodriguez LA, Castellsague J, Oliart AD. Hormone replacement therapy and risk of venous thromboembolism: populationbased case-control study. BMJ. 1997;314:796-800.
53. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized clinial trial. Arterioscler Thromb Vasc Biol. 1997;17:3071-3078.
54. Luyer MDP, Khosla S, Owen WG, Miller VM. Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women. J Clin Endocrinol Metab. 2001;86:3629-3634.
55. Schwartz SM, Petitti DB, Siscovick DS, et al. Stroke and use of low-dose oral contraceptives in young women. A pooled analysis of two US studies. Stroke. 1998;29:2284.
56. Giltay EJ, Gooren LJG, Emeis JJ, Kooistra T, Stehouwer CD. Oral, but not transdermal, administration of estrogens lowers tissue-type plasminogen activator levels in humans without affecting endothelial synthesis. Arterioscler Thromb Vasc Biol. 2001;20:1396-1403.
57. Petitti DB, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel HK. Stroke in users of low-dose oral contraceptives. N Engl J Med. 1996;335:8-15.
58. Petitti DB, Sidney S, Quensenberry CP, Jr, Bernstein A. Ischemic stroke and use of estrogen and estrogen/progestogen as hormone replacement therapy. Stroke. 1998;29:23-28.
59. Falkeborn M, Persson I, Terent A, Adami HO, Lithell H, Bergstrom R. Hormone replacement therapy and the risk of stroke. Arch Intern Med. 1993;153:1201-1209.
60. Schairer C, Adami HO, Hoover R, Persson I, Manson JE. Cause-specific mortality in women receiving hormone replacement therapy. Epidemiology. 1997;8:59-65.
61. Paganini-Hill A, Ross RK, Henderson BE. Postmenopausal oestrogen treatment and stroke: a prospective study. BMJ. 1988;297:519-522.
62. Pederson AT, Lidegaard O, Kreiner S, Ottesen B. Hormone replacement therapy and risk of non-fatal stroke. Lancet. 1997;350:1283.
63. Paganini-Hill A, Perez Barreto M. Stroke risk in older men and women: aspirin, estrogen, exercise, vitamins, and other factors. J Gend Specif Med. 2001;4:18-28.
64. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopasual estrogen replacement therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med. 1991;325:756-762.
65. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med. 1997;336:1769-1775.
66. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133:933-941.
67. O'Keefe JH, Kim SC, Hall RR, Cochran VC, Lawhorn SL, McCallister BD. Estrogen replacement therapy after coronary angioplasty in women. J Am Coll Cardiol. 1997;29:1-5.
68. Cauley JA, Seeley DG, Browner WS, et al. Estrogen replacement therapy and mortality among older women. The study of osteoporotic fractures. Arch Intern Med. 1997;157:2181-2187.
69. Fung MM, Barrett-Conner E, Bettencourt RR. Hormone replacement therapy and stroke risk in older women. J Womens Health. 1999;8:359-364.
70. Rodriguez C, Calle EE, Patel AV, Tatham LM, Jacobs EJ, Thun MJ. Effect of body mass on the association between estrogen replacement therapy and mortality among elderly US women. Am J Epidemiol. 2001;153:145-152.
71. Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormone therapy and risk of stroke. Circulation. 2001;103:638-642.
72. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Horowitz RI. Estrogen after ischemic stroke: effect of estrogen replacement on risk of recurrent stroke and death in the Women's estrogen for Stroke Trial (WEST). Stroke. 2001;32:329.
73. Wilson PW, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study. N Engl J Med. 1985;313:1038-1043.
74. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation. Analysis of 2012 participants in the SPAF I-III clinical trials. Stroke. 1999;30:1223-1229.
75. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001;345:1243-1249.
76. FitzGerald MJT. Blood supply of the brain. In: Neuroanatomy - Basic and Clinical. London, UK: WB Saunders. 1997:42-52.
77. Choi DW. Excitotoxic cell death. J Neurobiol. 1992;23:1261-1276.
78. Choi DW, Hartley DM. Calcium and glutamate-induced cortical neuronal death. Res Publ Assoc Res Nerv Ment Dis. 1993;71:23-34.
79. Choi DW. Calcium: still center-stage in hypoxic-ischemic neuronal death. Trends Neurosci. 1995;18:58-60.
80. Patel T, Gores GJ, Kaufmann SH. The role of proteases during apoptosis. FASEB. 1996;10:587-597.
81. Linnik MD, Zobrist RH, Hatfield MD. Evidence supporting a role for programmed cell death in focal cerebral ischemia in rats. Stroke. 1993;24:2002-2009.
82. MacManus JP, Hill IE, Huang ZG, Rasquinha I, Xue D, Buchan AM. DNA damage consistent with apoptosis in transient focal ischemic neocortex. Neuroreport. 1994;5:493-496.
83. Hisahara S, Shoji S, Okano H, Miura M. ICE/CED-3 family executes oligodendrocyte apoptosis by tumor necrosis factor. J Neurochem. 1997;69:10-20.
84. Hara H, Fink K, Endres M, et al. Attenuation of transient focal cerebral ischemic injury in transgenic mice expressing a mutant ICE inhibitory protein. J Cereb Blood Flow Metab. 1997;17:370-375.
85. Krajewski S, Mai JK, Krajewska M, Sikorska M, Mossakowski MJ, Reed JC. Upregulation of bax protein levels in neurons following cerebral ischemia. J Neurosci. 1995;15:6364-6375.
86. Asahi M, Hoshimaru M, Uemura Y, et al. Expression of interleukin-1 b converting enzyme gene family and bcl-2 gene family in the rat brain following permanent occlusion of the middle cerebral artery. J Cereb Blood Flow Metab 1997;17:11-18.
87. Martinou JC, Dubois-Dauphin M, Staple JK, et al. Overexpression of bcl-2 in transgenic mice protects neurons from naturally occurring cell death and experimental ischemia. Neuron. 1994;13:1017-1030.
88. Hall ED, Pazara KE, Linseman KL. Sex differences in postischemic neuronal necrosis in gerbils. J Cereb Blood Flow Metab. 1991;11:292-298.
89. Roof RL, Hall ED. Gender differences in acute CNS trauma and stroke: neuroprotective effects of estrogen and progesterone. J Neurotrauma. 2000;17:367-388.
90. Dubal DB, Kashon ML, Pettigrew LC, et al. Estradiol protects against ischemic injury. J Cereb Blood Flow Metab. 1998;18:1253-1258.
91. Rusa R, Alkayed NJ, Crain BJ, et al. 17β-Estradiol reduces stroke injury in estrogen-deficient female animals. Stroke. 1999;30:1665-1670.
92. Toung TJK, Traystman RJ, Hum PD. Estrogen-mediated neuroprotection after experimental stroke in male rats. Stroke. 1998;29:1666-1670.
93. Simpkins JW, Rajakumar G, Zhang YQ, et al. Estrogens may reduce mortality and ischemic damage caused by middle cerebral artery occlusion in the female rat. J Neurosurg. 1997;87:724-730.
94. Zhang YQ, Shi J, Rajakumar G, Day AL, Simpkins JW. Effects of gender and estradiol treatment on focal brain ischemia. Brain Res. 1998;784:321-324.
95. Wang Q, Santizo R, Baughman VL, Pelligrino DA, Iadecola C. Estrogen provides neuroprotection in transient forebrain ischemia through perfusion-independent mechanisms in rats. Stroke. 1999;30:630-637.
96. Emerson CS, Headrick JP, Vink R. Estrogen improves biochemical and neurologic outcome following traumatic brain injury in male rats, but not females. Brain Res. 1993;608:95-100.
97. Garcia-Estrada J, DelRio JA, Luquin S, Soriano E, Garcia-Segura LM. Gonadal hormones down-regulate reactive gliosis and astrocyte proliferation after a penetrating brain injury. Brain Res. 1993;628:271-278.
98. Roof RL, Duvdevani R, Stein DG. Gender influences outcome of brain injury: progesterone plays a protective role. Brain Res. 1991;607:333-336.
99. Saiyed M, Riker WK. Cholinergic and anticholinergic drug effects on survival during hypoxia: significant gender differences. J Pharmacol Exp Ther 1993;264:1146-1153.
100. Cadet K, Ladenheim B, Baum I, Carlson E, Epstein C. CuZn-superoxide dismutase (CuZnSOD) transgenic mice show resistance to the lethal effects of methylenedioxyamphetamine (MDA) and of methylenedioxymethamphetamine (MDMA). Brain Res. 1994;655:259-262.
101. Alkayed NJ, Harukuni I, Kimes AS, London ED, Traystman RJ, Hurn PD. Gender-linked brain injury in experimental stroke. Stroke. 1998;29:159-166.
102. Yang SH, Shi J, Day AL, Simpkins JW. Estradiol exerts neuroprotective effects when administered after ischemic insult. Stroke. 2000;31:745-750.
103. Dubal DB, Wise PM. Neuroprotective effects of estradiol in middleaged female rats. Endocrinology. 2001;142:43-48.
104. Green SG, Gridley KE, Simpkins JW. Estradiol protects against β-amyloid (25-35)-induced toxicity in SK-N-SH human neuroblastoma cells. Neurosci Lett. 1996;218:165-168.
105. Gridley KE, Green PS, Simpkins JW. Low concentrations of estradiol reduce β-amyloid (25-35)-induced toxicity, lipid peroxidation and glucose utilization in human SK-N-SH neuroblastoma cells. Brain Res. 1997;778:158-165.
106. L expression and β-amyloid-induced apoptosis: relevance to Alzheimer's disease. J Neurochem. 1999;72:1552-1563.
107. Goodman Y, Bruce AJ, Cheng B, Mattson MP. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid βpeptide toxicity in hippocampal neurons. J Neurochem. 1996;66:1836-1844.
108. Vedder H, Anthes N, Stumm G, Wurz C, Behl C, Krieg JC. Estrogen hormones reduce lipid peroxidation in cells and tissues of the central nervous system. J Neurochem. 1999;72:2531-2538.
109. Zaulyanov LL, Green PS, Simpkins JW. Glutamate receptor requirement for neuronal cell death from anoxia-reoxygenation: an in vitro model for assessment of the neuroprotective effects of estrogens. Cell Mol Neurobiol. 1999;19:705-718.
110. Wilson ME, Dubal DB, Wise PM. Estradiol protects against injuryinduced cell death in cortical explant cultures: a role for estrogen receptors. Brain Res. 2000;873:235-242,
111. Regan RF, Guo Y. Estrogens attenuate neuronal injury due to hemoglobin, chemical hypoxia, and excitatory amino acids in murine cortical cultures. Brain Res. 1997;764:133-140.
112. Behl C, Skutella T, Lezoualch F, et al. Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol. 1997;51:535-541.
113. Behl C, Widmann M, Trapp T, Holsboer F. 17β-Estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem Biophys Res Commun. 1998;216:473-482.
114. Singer CA, Figueroa-Masot CD, Batchelor RH, Dorsa DM. The mitogenactivated protein kinase pathway mediates estrogen neuroprotection after glutamate toxicity in primary cortical neurons. J Neurosci. 1999;19:2455-2463.
115. Singer CA, Rogers KL, Strickland TM, Dorsa DM. Estrogen protects primary cortical neurons from glutamate toxicity. Neurosci Lett. 1996;212:13-16.
116. Weaver CE, Jr, Park-Chung M, Gibbs TT, Farb DH. 17β-Estradiol protects against NMDA-induced excitotoxicity by direct inhibition of NMDA receptors. Brain Res. 1997;761:338-341.
117. Stoppini L, Buchs PA, Muller D. Lesion-induced neurite sprouting and synapse formation in hippocampal organotypic cultures. Neuroscience. 1993;57:985-994.
118. Zhang Y, Tounekti O, Akerman B, Goodyer CG, LeBlanc A. 17β-Estradiol induces an inhibitor of active caspases. J Neurosci. 2001;21:1-6.
119. Green PS, Bishop J, Simpkins JW. 17α-Estradiol exerts neuroprotective effects on SK-N-SH cells. J Neurosci. 1997;17:511-515.
120. Harukuni I, Hurn PD, Crain BJ. Deleterious effect of beta-estradiol in a rat model of transient forebrain ischemia. Brain Res. 2001;900:137-142.
121. Kondo Y, Suzuki K, Sakuma Y. Estrogen alleviates cognitive dysfunction following transient brain ischemia in ovariectomized gerbils. Neurosci Lett. 1997;238:45-48.
122. Lason W. Effects of estrogens on seizures and neurotoxicity. Pol J Pharmacol. 2000;52:59-62.
123. Tsai MJ, O'Malley B. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Ann Rev Biochem. 1994;63:451-486.
124. Toran-Allerand CD, Singh M, Setalo G. Novel mechanisms of estrogen action in the brain: new players in an old story. Front Neuroendocrinol. 1999;20:97-121.
125. Green PS, Simpkins JW. Neuroprotective effects of estrogens: potential mechanisms of action. Int J Dev Neurosci. 2000;18:347-358.
126. Singh M, Setalo G, Jr, Guan X, Warren M, Toran-Allerand CD. Estrogeninduced activation of mitogen-activated protein kinase in cerebral cortical explants: convergence of estrogen and neurotrophin signaling pathways. J Neurosci. 1999;19:1179-1188.
127. Murphy DD, Segal M. Morphological plasticity of dendritic spines in central neurons is mediated by activation of cAMP response element binding protein. Proc Natl Acad Sci USA. 1997;94:1482-1487.
128. Zhou Y, Watters JJ, Dorsa DM. Estrogen rapidly induces the phosphorylation of the cAMP response element binding protein in rat brain. Endocrinology. 1996;137:2163-2166.
129. McEwen BS, Alves SE, Bulloch K, Weiland NG. Ovarian steroids and the brain: implications for cognition and aging. Neurology. 1997;48:S8-S15.
130. Woolley CS, McEwen BS. Estradiol mediates fluctuation in hippocampal synapse density during the estrous cycle in the adult rat. J Neurosci. 1992;12:2549-2554.
131. Murphy DD, Cole NB, Segal M. Brain-derived neurotrophic factor mediates estradiol-induced dendritic spine formation in hippocampal neurons. Proc Natl Acad Sci USA. 1998;95:11412-11417.
132. McEwen BS, Tanapat P, Weiland NG. Inhibition of dendritic spine induction on hippocampal CA1 pyramidal neurons by a nonsteroidal estrogen antagonist in female rats. Endocrinology. 1999;140:1044-1047.
133. Gould E, Woolley CS, Frankfurt M, McEwen B5. Gonadal steroids regulate dendritic spine density in hippocampal pyramidal cells in adulthood. J Neurosci. 1990;10:1286-1291.
134. Sohrabji F, Miranda RC, Toran-Allerand CD. Estrogen differentially regulates estrogen and nerve growth factor receptor mRNAs in adult sensory neurons. J Neurosci. 1994;14:459-471.
135. Singh M, Meyer EM, Simpkins JW. The effect of ovariectomy and estradiol replacement on brain-derived neurotrophic factor messenger ribonucleic acid expression in cortical and hippocampal brain regions of female Sprague-Dawley rats. Endocrinology. 1995;136:2320-2324.
136. McMillan PJ, Singer CA, Dorsa DM. The effects of ovariectomy and estrogen replacement on trkA and choline acetyltransferase mRNA expression in the basal forebrain on the adult female Sprague-Dawley rat. J Neurosci. 1996;16:1860-1865.
137. Gibbs RB, Wu D, Hersh LB, Pfaff DW. Effects of estrogen replacement on the relative levels of choline acetyltransferase, trkA, and nerve growth factor messenger RNAs in the basal forebrain and hippocampal formation of adult rats. Exp Neurol. 1994;129:70-80.
138. Singer CA, Rogers KL, Dorsa DM. Modulation of Bcl-2 expression: a potential component of estrogen protection in NT2 neurons. Neuroreport. 1998;9:2565-2568.
139. Dubal DB, Shughrue PJ, Wilson ME, Merchenthaler I, Wise PM. Estradiol modulates Bcl-2 in cerebral ischemia: a potential role for estrogen receptors. J Neurosci. 1999; 19:6385-6393.
140. Dubal DB, Zhu B, Yu B, et al. Estrogen receptor-α, not -β, is a critical link in estradiol-mediated protection against brain injury. Proc Natl Acad Sci U S A. 2001;98:1952-1957.
141. Rau SW, Dubal DB, Wise PM. Immediate early gene regulation by estradiol in ischemic injury. Soc Neurosci. 2000;26:778.
142. Dubal DB, Wilson ME, Shughrue PJ, Merchenthaler I, Wise PM. Induction of galanin gene expression in estradiol-mediated neuroprotection against cerebral ischemia. Soc Neurosci. 1999;25:1449.
143. Böttner M, Dubal DB, Rau SW, Wise PM. Activin gene expression increases after stroke injury: modulation by estradiol. Soc Neurosci Abstr. 2001;27:1165.
144. Pelligrino DA, Galea E. Estrogen and cerebrovascular physiology and pathophysiology. Jpn J Pharmacol. 2002;86:137-158.
145. Green PS, Gordon K, Simpkins JW. Phenolic A ring requirement for the neuroprotective effects of steroids. J Steroid Biochem Mol Biol. 1997;63:229-235.
146. Subbiah MT, Kessel B, Agrawal M, Raian R, Abplanalp W, Rymaszewski A. Antioxidant potential of specific estrogens on lipid peroxidation. J Clin Endocrinol Metab. 1993;77:1095-1097.
147. Green PS, Gridley KE, Simpkins JW. Nuclear estrogen receptor-independent neuroprotection by estratrienes: a novel interaction with glutathione. Neuroscience. 1998;84:7-10.
148. Culmsee C, Vedder H, Ravati A, et al. Neuroprotection by estrogens in a mouse model of focal cerebral ischemia and in cultured neurons: evidence for a receptor-independent antioxidative mechanism. J Cereb Blood Flow Metab. 1999;19:1263-1269.